NICE (National Institute for Health and Clinical Evidence) has produced guidance which does not recommend bevacizumab in combination with capecitabine as first-line treatment for mestatistic breast cancer, "when other chemotherapy..is not appropriate, or taxanes or anthracyclines have been given in the past 12 months." Although NICE investigated a number of factors before making this declaration, including how well the proposed treatment worked, cost, and special considerations that could potentially extend the lives of terminal cancer patients, there was not enough evidence provided to justofy this treatment option.
To read more about this guidance, click here.
No comments:
Post a Comment